{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:07:07Z","timestamp":1784020027020,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer (BC) brain metastases (BM) treatment involves radiotherapy (RT), surgery, and CNS-penetrating systemic therapies. This study evaluated treatment patterns in brain RT and corresponding survival outcomes among patients with BC BM using the National Cancer Database (NCDB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients diagnosed with BC BM between 2010 and 2021 were identified. RT was categorized as whole brain (WBRT) vs. stereotactic (SRT). We fitted Overlap Propensity Score Weighting (OPSW) Cox models to account for confounders affecting OS. Variables included age, race, ethnicity, Charlson\u2013Deyo score, insurance, molecular subtype, facility type, and systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 8909 patients with BC BM, 43.4% received brain RT (74.1% WBRT, 25.9% SRT). Patients that are African American, lower income, urban, triple-negative, or at community facilities were more likely to receive WBRT over SRT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Median OS for the entire cohort was 10.9\u00a0months (95% CI 10.4\u201311.5). Systemic therapy alone (HR 0.40, 95% CI 0.36\u20130.43) or combined with RT (HR 0.38, 95% CI 0.35\u20130.42) improved OS; however RT alone did not improve survival on MVA (HR 0.96 (95% CI 0.91\u20131.02). Among RT recipients, SRT was associated with improved OS vs. WBRT (HR 0.76, 95% CI 0.69\u20130.83). Older age, comorbidities, lack of insurance, community facilities, and aggressive subtypes were associated with worse OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment patterns, particularly access to SRT, differ among BC BM patients therefore highlighting the need for strategies to promote equitable implementation of evidence-based guidelines. More prospective trials are also needed to establish evidence-based treatment standards for BC BM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07955-z","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:56:02Z","timestamp":1776840962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation treatment patterns for breast cancer brain metastases: an NCDB analysis"],"prefix":"10.1007","volume":"217","author":[{"given":"Thamilini","family":"Pathmarajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniya","family":"Gokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Slover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanun","family":"Jitwatcharakomol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Andraos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Grecula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dukajin","family":"Blakaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Chakravarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin R.","family":"Jhawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"4","key":"7955_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial. JAMA 316(4):401\u2013409","journal-title":"JAMA"},{"key":"7955_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.0076","author":"AA Aizer","year":"2026","unstructured":"Aizer AA et al (2026) Treatment for brain metastases with stereotactic radiation vs hippocampal-avoidance whole brain radiation: a randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2026.0076","journal-title":"JAMA"},{"issue":"5","key":"7955_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA et al (2022) Treatment for brain metastases: asco-sno-astro guideline. J Clin Oncol 40(5):492\u2013516","journal-title":"J Clin Oncol"},{"issue":"1","key":"7955_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","volume":"21","author":"C Horbinski","year":"2023","unstructured":"Horbinski C et al (2023) Central nervous system cancers, version 2.2022. J Natl Compr Cancer Netw 21(1):12\u201320","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"7955_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","volume":"15","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387\u2013395","journal-title":"Lancet Oncol"},{"key":"7955_CR6","unstructured":"Nabors LB, GP, Patel TR (2025) NCCN guidelines version 3.2025 limited brain metastases"},{"issue":"12","key":"7955_CR7","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.6004\/jnccn.2017.7003","volume":"15","author":"BH Kann","year":"2017","unstructured":"Kann BH et al (2017) Radiosurgery for brain metastases: changing practice patterns and disparities in the united states. J Natl Compr Canc Netw 15(12):1494\u20131502","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"7955_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s11060-025-05178-8","volume":"175","author":"JJ Shih","year":"2025","unstructured":"Shih JJ et al (2025) Stereotactic radiosurgery for brain metastases: evolving practice patterns from the National Cancer Database (2004\u20132020). J Neurooncol 175(3):1211\u20131225","journal-title":"J Neurooncol"},{"issue":"2","key":"7955_CR9","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1016\/j.clbc.2018.11.001","volume":"19","author":"W Mainwaring","year":"2019","unstructured":"Mainwaring W et al (2019) Stereotactic radiosurgery versus whole brain radiation therapy: a propensity score analysis and predictors of care for patients with brain metastases from breast cancer. Clin Breast Cancer 19(2):e343\u2013e351","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"7955_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1793","volume":"4","author":"DX Yang","year":"2021","unstructured":"Yang DX et al (2021) Prevalence of missing data in the national cancer database and association with overall survival. JAMA Netw Open 4(3):e211793","journal-title":"JAMA Netw Open"},{"issue":"521","key":"7955_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"LKLM Fan","year":"2018","unstructured":"Fan LKLM, Laslavsky A (2018) Balancing covariates via propensity score weighting. J Am Stat Associ 113(521):390\u2013400","journal-title":"J Am Stat Associ"},{"issue":"23","key":"7955_CR12","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ (2020) Overlap weighting a propensity score method that mimics attributes of a randomized clinical trial. JAMA 323(23):2417\u20132418","journal-title":"JAMA"},{"issue":"3","key":"7955_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399\u2013424","journal-title":"Multivariate Behav Res"},{"issue":"3","key":"7955_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11060-024-04748-6","volume":"169","author":"D Gomez","year":"2024","unstructured":"Gomez D et al (2024) Incidence of brain metastasis according to patient race and primary cancer origin: a systematic review. J Neurooncol 169(3):457\u2013467","journal-title":"J Neurooncol"},{"issue":"4","key":"7955_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/cncr.24087","volume":"115","author":"M Schootman","year":"2009","unstructured":"Schootman M et al (2009) Racial disparities in the development of breast cancer metastases among older women. Cancer 115(4):731\u2013740","journal-title":"Cancer"},{"issue":"22","key":"7955_CR16","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.7150\/jca.32435","volume":"10","author":"J Wu","year":"2019","unstructured":"Wu J et al (2019) Racial disparities in young-onset patients with colorectal, breast and testicular cancer. J Cancer 10(22):5388\u20135396","journal-title":"J Cancer"},{"issue":"1","key":"7955_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-018-4956-y","volume":"173","author":"JX Ren","year":"2019","unstructured":"Ren JX et al (2019) Racial\/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat 173(1):225\u2013237","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7955_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-024-07321-x","volume":"206","author":"A Hijazi","year":"2024","unstructured":"Hijazi A et al (2024) Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis. Breast Cancer Res Treat 206(3):527\u2013541","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7955_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101213","volume":"8","author":"K Riecke","year":"2023","unstructured":"Riecke K et al (2023) Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. ESMO Open 8(3):101213","journal-title":"ESMO Open"},{"issue":"1","key":"7955_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41467-022-27987-5","volume":"13","author":"N Cosgrove","year":"2022","unstructured":"Cosgrove N et al (2022) Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nat Commun 13(1):514","journal-title":"Nat Commun"},{"issue":"7","key":"7955_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK et al (2020) Tucatinib, Trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597\u2013609","journal-title":"N Engl J Med"},{"issue":"23","key":"7955_CR22","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU et al (2020) Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB Trial. J Clin Oncol 38(23):2610\u20132619","journal-title":"J Clin Oncol"},{"key":"7955_CR23","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","volume":"34","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA et al (2023) A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03. Ann Oncol 34:S335\u2013S336","journal-title":"Ann Oncol"},{"issue":"9","key":"7955_CR24","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R et al (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28(9):1840\u20131847","journal-title":"Nat Med"},{"issue":"7","key":"7955_CR25","first-page":"S663","volume":"33","author":"A Bardia","year":"2022","unstructured":"Bardia A et al (2022) ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC). Ann Oncol 33(7):S663\u2013S664","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07955-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07955-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07955-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:29:57Z","timestamp":1784017797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07955-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7955"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07955-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8545320\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"26"}}